Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Vesicare Generic Name & Formulations
Legal Class
Rx
General Description
Solifenacin succinate 5mg, 10mg; tabs.
Pharmacological Class
Muscarinic antagonist.
See Also
How Supplied
Tabs—30, 90; Susp—150mL
Manufacturer
Generic Availability
NO
Vesicare Indications
Indications
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Vesicare Dosage and Administration
Adult
Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl <30mL/min/1.73m2), moderate hepatic impairment (Child-Pugh B), or concomitant strong CYP3A4 inhibitors: max 5mg once daily.
Children
Not established.
Vesicare Contraindications
Contraindications
For tabs: urinary retention. For tabs & susp: gastric retention, uncontrolled narrow-angle glaucoma.
Vesicare Boxed Warnings
Not Applicable
Vesicare Warnings/Precautions
Warnings/Precautions
Significant bladder outlet obstruction, decreased GI motility, high risk or history of QT prolongation, severe hepatic impairment (Child-Pugh C): not recommended. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider dose reduction or discontinuation if occurs. Severe renal or moderate hepatic impairment. Pregnancy. Nursing mothers.
Vesicare Pharmacokinetics
See Literature
Vesicare Interactions
Interactions
Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.
Vesicare Adverse Reactions
Adverse Reactions
Dry mouth, constipation, UTI, blurred vision; CNS effects (eg, headache, confusion, hallucination, somnolence); angioedema and anaphylactic reactions (discontinue if occurs).
Vesicare Clinical Trials
See Literature
Vesicare Note
Not Applicable
Vesicare Patient Counseling
See Literature
Images
